AI and Cancer Research ── Cancer biology ── 2026-10-03
Cancer molecular biology and AI
- Abstract
Although genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes.
Significance: This work describes MutationProjector, a tumor genomic foundation model pretrained on more than 30,000 tumors. It maps mutations to biological states for diagnosis and treatment, achieving state-of-the-art performance in predicting therapy resistance and identifying biomarkers such as KMT2D (sensitivity) and SMARCA4/STK11 coalterations (resistance).
Journal IF-equivalent: 7.7 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Kong J, Lee I, Boecher D, Singhal A, Kelly MR, Moon J, et al. A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response. Cancer Discov. 2026 May 26;16(10):2021-36. doi:10.1158/2159-8290.cd-25-1735. PMID: 42188872; PMCID: PMC13367315.Checked: Abstract only - Abstract
Background: Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predicting large-scale biomarkers directly from hematoxylin and eosin (H&E)-stained whole slide images (WSIs).
Methods: We introduce Rapid and Intelligent Detector for Genetic Estimation (RIDGE) , a deep learning-based artificial intelligence (AI) system for gene expression signatures and standard biomarkers automated prediction in annotation-free whole slide images. RIDGE was developed and validated using 4983 WSIs from 4680 patients across 12 solid tumors from The Cancer Genome Atlas (TCGA). Its feasibility was further confirmed in an external validation cohort of 221 WSIs from 105 colorectal cancer patients from The Clinical Proteomic Tumor Analysis Consortium (CPTAC), specifically for predicting microsatellite instability (MSI) status.
Results: RIDGE achieved an overall area under the curve (AUC) of 0.763 (95% CI, 0.724–0.802) across 12 cancer types. In the external CPTAC cohort, RIDGE demonstrated an AUC of 0.769 (95% CI 0.686–0.841) for MSI status prediction, underscoring its reproducibility. We observed that the morphological visual characteristics could be captured by our model, enabling the gene expression signatures and standard biomarkers highly detectable directly from WSIs.
Conclusions: These findings highlight RIDGE’s potential to significantly expedite cancer screening and personalized therapy. Moreover, RIDGE offers an AI-assisted assessment approach with high predictive performance to elucidate and quantify genotype-phenotype relationships in cancer, demonstrating its promise in advancing the field of cancer diagnostics. Clinical trial number Not applicable.
Journal IF-equivalent: 3.8 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Xi H, Feng X, Lu Y, Li G, Zhang Y, Li J, et al. Deep learning-based large-scale pan-cancer multiple biomarkers prediction using RIDGE with pathological images. BMC Med Imaging. 2026 Sep 30 [Epub ahead of print]. doi:10.1186/s12880-026-02695-4.Checked: Abstract only - Abstract
BACKGROUND: The spatial tumor immune microenvironment (TIME) determines therapy response in colorectal cancer liver metastases (CRLM). To overcome biopsy sampling bias, this study investigates multimodal macroscopic image fractal dynamics to non-invasively map immune physical barriers and metabolic states, constructing a multi-scale immune-radiomics joint score (IRJS) for robust prognostic stratification and exploratory assessment of treatment resistance. MATERIALS AND METHODS: This dual-center observational study enrolled 270 CRLM patients with dual-modality imaging (contrast-enhanced magnetic resonance imaging, CE-MRI, 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography, 18 F-FDG PET/CT) and digital spatial pathology. Patients were spatiotemporally divided into training (n=150), prospective temporal validation (n=45), and external validation (n=75) cohorts. Structural (FD_MRI) and metabolic (FD_PET) fractal dimensions were combined with the systemic immune-inflammation index (SII) and KRAS status to build the IRJS using XGBoost, utilizing the SHAP framework to evaluate mapping mechanisms. RESULTS: FD_MRI positively correlated with α-SMA + pro-fibrotic stromal density ( r = 0.684), which may reflect the mechanical barrier excluding CD8 + T cells. FD_PET showed a significant association with core hypoxia (HIF-1α) and systemic immune exhaustion. IRJS robustly identified the immune-inflamed phenotype across training, temporal, and external validation cohorts (AUCs: 0.921, 0.886, 0.862, respectively). The IRJS-identified inflamed phenotype was an independent protective factor for overall survival (HR = 0.31, P P < 0.001) and net clinical benefit in decision curve analysis. CONCLUSION: Dual-modal fractal dynamics provide non-invasive surrogate markers for mechanical constraints and metabolic exhaustion in CRLM. The IRJS model enables robust spatiotemporal assessment of immune evasion, offering multidisciplinary teams a potential framework to explore non-invasive biopsy decisions, prognostic stratification, and provide exploratory insights into potential immunotherapy resistance.
Journal IF-equivalent: 5.5 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Ziyi G, Zhou W, Zou K. Mapping the physical topology of the tumor immune microenvironment: macroscopic image fractals as surrogate markers for immune exclusion phenotype and treatment resistance in colorectal cancer liver metastases. Front Immunol. 2026 Sep 17;17:1889571. doi:10.3389/fimmu.2026.1889571. PMID: 42824375.Checked: Abstract only